(MedPage Today) — Type 2 diabetes patients starting on SGLT2 inhibitors had a sightly lower risk of autoimmune rheumatic diseases compared with those initiating sulfonylureas, a large retrospective Korean study found.
Over a median follow-up…
Source link : https://www.medpagetoday.com/rheumatology/generalrheumatology/117970
Author :
Publish date : 2025-10-15 22:30:00
Copyright for syndicated content belongs to the linked Source.
